Tang Capital Management Reports 8.2% Stake in Fulcrum Therapeutics, Inc.

On June 10, 2026, Tang Capital Management, LLC, led by Kevin Tang, filed a Schedule 13G indicating a new substantial position in Fulcrum Therapeutics, Inc. (FULC). As of the event date on June 3, 2026, the reporting group collectively beneficially owns 5,451,800 shares of common stock, representing 8.2% of the company's outstanding shares. This filing is a joint submission involving several entities, including Tang Capital Partners, LP, Tang Capital Partners International, LP, and Tang Capital Partners III and IV, Inc. Kevin Tang, as the manager of TCM and CEO of the associated corporations, shares voting and dispositive power over the reported shares. The filing specifies that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. This significant investment highlights a major new institutional stake in the Cambridge-based biopharmaceutical company, based on approximately 66.6 million shares outstanding as reported in Fulcrum's recent quarterly filings.